Oral fingolimod (FTY720) therapy reduces blood brain barrier breakdown, microglial activation, and leukocyte recruitment in a focal DTH model of multiple sclerosis

被引：0
|
作者：
Anthony, D. C.
Sibson, N. R.
Losey, P.
Piani, D.
Leppert, D.
机构：
[1] Univ Oxford, Oxford, England
[2] Novartis Pharma AG, Basel, Switzerland
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S275 / S276
页数：2
相关论文
共 15 条
  • [1] Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
    Sharma, Sushil
    Mathur, A. G.
    Pradhan, Sapna
    Singh, D. B.
    Gupta, Sparsh
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2011, 2 (01) : 49 - 51
  • [2] A Mechanistically Novel, First Oral Therapy for Multiple Sclerosis: The Development of Fingolimod (FTY720, Gilenya)
    Chun, Jerold
    Brinkmann, Volker
    DISCOVERY MEDICINE, 2011, 12 (64) : 213 - 228
  • [3] Therapeutic Effects of Oral Fingolimod (FTY720) in an Animal Model of the Progressive Disability of Multiple Sclerosis
    Pachner, Andrew
    Apte, Priyanka
    Brady, Jennifer
    Li, Libin
    NEUROLOGY, 2010, 74 (09) : A562 - A563
  • [4] The Peripheral Blood T-cell Subset Dynamics Of Oral Fingolimod (FTY720)-Treated Multiple Sclerosis Patients
    Song, Z. Y.
    Kawano, Y.
    Yoshimura, S.
    Watanabe, M.
    Imamura, S.
    Yonekawa, T.
    Masaki, K.
    Matsushita, T.
    Yamasaki, R.
    Kira, J.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 930 - 930
  • [5] Oral Therapy strategies in Multiple Sclerosis: 2-Year Data of Phase-II-study to Fingolimod (FTY720)
    不详
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2009, 77 (07) : 374 - 374
  • [6] FTY720 restores function to somatosensory pathways and reverses blood-brain-barrier leakage in a chronic demyelinating model of multiple sclerosis
    Foster, CA
    Storch, MK
    Balatoni, B
    Romauch, M
    Weissert, R
    NEUROLOGY, 2006, 66 (05) : 306 - 306
  • [7] Oral fingolimod (FTY720) treatment reduces peripheral IL-17-producing TH17 cells in patients with multiple sclerosis
    Mehling, Matthias
    Lindberg, Raija L.
    Kuhle, Jens
    Vedrine, Corinne
    Kappos, Ludwig
    Brinkmann, Volker
    MULTIPLE SCLEROSIS, 2008, 14 : S234 - S234
  • [8] In vivo positron emission tomography imaging demonstrates diminished microglial activation after FTY720 treatment in an animal model of multiple sclerosis
    Airas, L.
    Dickens, A.
    Haaparanta-Solin, M.
    Anthony, D.
    Rinne, J.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 136 - 137
  • [9] In Vivo micro-PET Imaging Demonstrates Diminished Microglial Activation after FTY720 Treatment in an Animal Model of Multiple Sclerosis
    Airas, Laura
    Dickens, Alex
    Haaparanta-Solin, Merja
    Anthony, Daniel
    Rinne, Juha
    NEUROLOGY, 2013, 80
  • [10] Fingolimod (FTY720) reduces disease progression, but does not exacerbate viral load in Theiler's murine encephalomyelitis virus-induced demyelinating disease model of multiple sclerosis
    Pachner, A.
    Brady, J.
    Li, L.
    Apte, P.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S178 - S178
12